MDS Pharma Services has appointed two industry experts as part of a growth strategy to sharpen the focus on new business opportunities in drug and biopharmaceutical development. Dr. Claudio Carini, a globally recognized leader for his work in developing and applying biomarkers to indicate the risk, presence and progression of diseases, has been named vice president of translational medicine. Suzanne Sensabaugh, a global leader recognized for her regulatory expertise in helping clients in the development of biopharmaceuticals, has been named vice president of biopharmaceutical development
Dr. Carini will manage and direct The Biomarker Alliance, which provides one-stop shopping for biomarker service providers to join together to design and execute a wide range of biomarker discovery and development programs. Dr. Carini has more than 25 years experience as a physician and scientist in industry and academia. He most recently served as vice president and global head of biomarkers at Roche Pharma and is well known for his development of several products to provide anti-infective and anti-inflammatory relief for patients.
Ms. Sensabaugh will be responsible for leading the consulting group responsible for development of biopharmaceuticals. Most recently she served as vice president for U.S. Regulatory Affairs and senior director for global biogenerics at Teva Pharmaceuticals. She has more than 10 years of experience at the FDA Center for Biologics Evaluation.